Minireviews
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107700
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107700
Progress in the study of therapeutic strategies for hepatoblastoma in children
Ran Tang, Shi-Qin Qi, Tao Zhang, Zhu-Bin Pan, Jia-Hua Xu
Ran Tang, Shi-Qin Qi, Tao Zhang, Zhu-Bin Pan, Department of Pediatric Surgery, Anhui Provincial Children’s Hospital, Hefei 231000, Anhui Province, China
Jia-Hua Xu, Department of Gastroenterology, Anhui Provincial Children’s Hospital, Hefei 231000, Anhui Province, China
Co-corresponding authors: Zhu-Bin Pan and Jia-Hua Xu.
Author contributions: Tang R and Qi SQ contributed equally to the literature review, data analysis, and manuscript drafting; Zhang T participated in the critical revision of the manuscript for important intellectual content; Pan ZB and Xu JH provided overall guidance, supervised the study, and contributed to manuscript editing; Pan ZB and Xu JH are jointly responsible for the final approval of the version to be published, contributed equally to this article, and are the co-corresponding authors of this manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia-Hua Xu, Professor, Department of Gastroenterology, Anhui Provincial Children’s Hospital, Wangjiang Street, Hefei 231000, Anhui Province, China. xujiahua.cn@163.com
Received: March 28, 2025
Revised: April 10, 2025
Accepted: May 12, 2025
Published online: June 15, 2025
Processing time: 78 Days and 0.1 Hours
Core Tip

Core Tip: Hepatoblastoma (HB) is the most common malignant liver tumor in children, and its treatment has evolved remarkably in recent years. This review summarizes the latest advances in HB epidemiology, molecular classification, risk stratification, surgical innovations, and systemic therapies. Emphasis is placed on current challenges and critical comparisons of treatment modalities, such as surgical timing, neoadjuvant chemotherapy, liver transplantation, and targeted therapies. By integrating updated evidence and proposing future research directions, this article provides practical insights to guide clinical decision-making and promote individualized, precision therapy in pediatric HB.